Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT05685004

Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)

This randomized study is designed to compare the combination of TVI-Brain-1 immunotherapy and standard therapy compared to standard therapy alone as a treatment for newly diagnosed MGMT unmethylated glioblastoma patients. The patients' own cancer cells collected after surgery are combined into a vaccine to produce an immune response that significantly increases the number of cancer neoantigen-specific effector T cell precursors in the patient's body. These cancer neoantigen-specific T cells are harvested from the blood, subsequently stimulated and expanded, and infused back into the patient.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Glioblastoma Multiforme of Brain

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2 / Phase 3

Primary location

Center for Neurosciences, Tucson, Arizona, United States

Loading trial locations.

About this study

This randomized study is designed to compare the combination of TVI-Brain-1 immunotherapy and standard therapy compared to standard therapy alone as a treatment for newly diagnosed MGMT unmethylated glioblastoma patients. The general procedures include the collection and testing of cancer tissue samples after surgery and chemoradiation therapy (radiation and temozolomide). For the patients randomized into the investigational study treatment group, they will also receive two vaccinations created from their own cancer cells, undergo leukapheresis to collect immune T-cells from their blood, and transfer of those activated effector T-cells after chemoradiation therapy. All patients are followed with MRIs at follow-up visits.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Newly diagnosed MGMT unmethylated glioblastoma multiforme (no prior treatment)
  • Sufficient cancer tissue obtained to allow for manufacture of autologous cancer cell vaccines
  • The attenuated autologous cancer cell product generated has satisfied the product release criteria as determined by the sponsor quality control department
  • Medical history, physical examination and laboratory testing performed within approximately 7 days before enrollment revealing kidney and liver organ function within normal limits
  • not currently receiving glucocorticoids and have been off glucocorticoids for at least 24 hours prior to vaccination as well as when they receive the T cell infusion.
  • Patient function assessment (Karnofsky score is > 60)
  • a life expectancy of > 12 weeks.
  • Hemoglobin is > 10 g/dL (may be transfused)
  • White blood cell count is > 3,000 cells/microliter (mcL) of blood.
  • Platelet count is > 100,000 platelets per mcL of blood (transfusion independent)
  • Lymphocyte count is > 1,000 cells/mcL of blood.

Exclusion criteria

  • another concomitant life-threatening disease (not including glioblastoma multiforme)
  • a second malignancy that is not in remission as determined by the clinical investigator. Exception: squamous or basal cell carcinoma of the skin.
  • requirement for treatment with glucocorticoids to control brain swelling
  • presence of active autoimmune disease that is currently being actively treated.
  • psychological, familial, sociological or geographical conditions that do not permit adequate medical follow-up and compliance with the study protocol.
  • Current pregnancy or a plan to become pregnant within 1-year following the study.

Treatment and study plan

TVI-Brain-1

Biological

Attenuated autologous cancer cells and activated autologous blood-derived t cells

Standard of care

Procedure

Surgery for tumor removal or debulking to minimize tumor burden

Radiotherapy

Radiation

Conformal radiotherapy consists of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily five days per week (Monday through Friday) over a period of six weeks.

Temozolomide

Drug

All Subjects receive 75 mg/m2 of temozolomide daily beginning on the first day of radiotherapy and continuing until the completion of radiotherapy. Standard of care Subjects will also receive adjuvant temozolomide .

Other names: Chemotherapy

Primary outcomes

  1. Survival

    Time frame: From date of randomization until the date of death from any cause assessed up to 24 months after randomization.

    All Subjects will be evaluated and contacted to evaluate their status

Secondary outcomes

  1. Progression-free survival

    Time frame: From date of randomization until the date of first documented progression assessed up to 24 months after randomization

    Time to progression is evaluated by review and analysis of serial MRI's taken at specific Time to progression is evaluated by review and analysis of serial MRI's taken at specific timepoints

Other outcomes

  1. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

    Time frame: Through study completion, an average of 2 years

    Assessment of changes in patient through Physical Examination

  2. Immunogenicity

    Time frame: Assessed at 24 hours after each vaccine administration

    Delayed-type hypersensitivity (DTH) skin testing using attenuated autologous cancer cells will be performed to assess the immunogenicity of the Subject's cancer.

  3. Other genetic and immunologic parameters

    Time frame: Assessed at 24 hours after each vaccine administration

    The study is also designed to determine whether a wide variety of genetic and immunologic parameters that are monitored during and following treatment correlate with clinical outcomes

Sponsors and collaborators

Lead sponsor

TVAX Biomedical

Industry

Registry information

Official study title

Randomized Phase 2b Study of Safety And Efficacy Of TVI-Brain-1 Combined With Conformal Radiotherapy And Temozolomide Vs Standard Therapy In Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)

Important dates

Study start
2023
Primary completion
2026
Study completion
2027
First posted
Jan 13, 2023
Registry last updated
Jul 1, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.